Kenvue Inc. (KVUE) Balance Sheet

The sequential increase in equity from $9.7B in 2024Q4 to $10.6B in 2026Q2, despite negative retained earnings, suggests that capital injections or other comprehensive income are offsetting accumulated deficits. This stabilization aligns with the company's transition to full independence, but the persistent negative retained earnings warrant monitoring as they may limit future dividend capacity.

The D/E ratio peaked at 0.90 in 2024Q4 and has since declined to 0.80, suggesting deleveraging efforts. However, total debt remains elevated at $8.5B, and with cash flat at $1.1B, net debt is substantial. This leverage appears strategic, supporting dividends and operations, but investors should monitor interest coverage as rates fluctuate.

The heavy goodwill concentration suggests that past acquisitions, likely from the J&J carve-out, are a key driver of the balance sheet. This raises impairment risk if growth in Skin Health or Self Care underperforms. The low PPE relative to assets confirms a marketing-driven business model, but the lack of tangible assets may limit collateral value.

The shift from positive retained earnings of $342M in 2024Q1 to a deficit of $70M in 2026Q2 reflects separation costs and dividend payouts exceeding net income. This suggests that the company is returning capital to shareholders faster than it is generating earnings, which may not be sustainable without debt or asset sales. The equity base is supported by other components, but the trend warrants close observation.

With a current ratio of 1.01 in 2026Q2, the company has just enough current assets to cover current liabilities, leaving little room for working capital shocks. Cash of $1.1B is modest relative to total debt of $8.5B, suggesting reliance on operating cash flow and refinancing. This thin liquidity position may constrain flexibility for M&A or unexpected downturns.